Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HuMax IL8 - Bristol-Myers Squibb/Genmab

Drug Profile

HuMax IL8 - Bristol-Myers Squibb/Genmab

Alternative Names: anti-IL8 mAb - Bristol-Myers Squibb/Genmab; BMS-986253; HuMax-IL8; HuMax-Inflam; HuMax®-IL8; MDX 018

Latest Information Update: 08 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genmab; Medarex
  • Developer Bristol-Myers Squibb; Columbia University; Genmab; Medarex
  • Class Anti-inflammatories; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Interleukin 8 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Prostate cancer; Solid tumours
  • Discontinued Autoimmune disorders; Glioblastoma; Palmoplantar pustulosis

Most Recent Events

  • 15 Oct 2019 Icahn School of Medicine at Mount Sinai and Bristol-Myers Squibb plans a phase II trial for Non-small cell lung cancer and Hepatocellular carcinoma (Neoadjuvant therapy, In adults, In the elderly) in USA in November 2019 (Parenteral) (NCT04123379)
  • 08 Aug 2019 NYU Langone Health plans a phase II trial for Liver cancer (Late-stage disease, Combination therapy, First-line therapy) in August 2019 (NCT04050462)
  • 21 Jan 2019 Phase-I/II clinical trials in Prostate cancer (Combination therapy) in USA (IV) (NCT03689699)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top